Organisation: Amgen

Five things to watch in US Supreme Court oral argument in Amgen v Sanofi

Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112

15 March 2023